Isa Sakiru O, Buhari Olajide, Adeniran-Isa Muminat, Baral Nischit, Adhikari Govinda, AbdulAzeem Basel, Savarapu Pramod, Adekolujo Oyebimpe, Hassan Mustafa, Adeboye Adedayo
Department of Medicine, McLaren Flint, Flint, MI, USA.
Clin Med Insights Cardiol. 2021 Dec 4;15:11795468211058761. doi: 10.1177/11795468211058761. eCollection 2021.
There has been a steady and consistent rise in the use of left ventricular assist devices in the management of patients with advanced heart failure. Hypothyroidism also remains one of the most common endocrine conditions with a significant impact on the development and overall outcomes of heart failure. The authors analyzed the National Inpatient Sample to evaluate the effect of hypothyroidism on the in-hospital outcomes of patients with end-stage heart failure following the placement of left ventricular assist device.
The national inpatient sample was queried to identify all adult patients who had LVAD placement from 2004 to 2014. They were subsequently divided into those with hypothyroidism and those without hypothyroidism. The primary outcome was in-hospital mortality. Other outcomes were acute kidney injury, length, and cost of hospitalization. Logistic regression models were created to determine the outcomes of interest.
Of 2643 patients in the study, 5.4% had hypothyroidism, and 94.6% did not. The hypothyroid patients were significantly older compared to the non-hypothyroid patients (mean age 58.6 years vs 49.95 years, -value <.0001). Both groups had similar gender composition. In-hospital mortality was similar across both groups. However, there was a higher incidence of acute kidney injury (AKI) in the hypothyroid group (adjusted odds ratio [aOR 1.83, -value <.001]). Hypothyroid patients had longer hospital stays (adjusted mean difference [aMD] 5.19, -value .0001). Hospital charges were also higher in the hypothyroid group.
This study found that LVAD is associated with longer hospital stay in hypothyroid patients with heart failure.
在晚期心力衰竭患者的治疗中,左心室辅助装置的使用一直在稳步且持续增加。甲状腺功能减退症仍是最常见的内分泌疾病之一,对心力衰竭的发展和总体预后有重大影响。作者分析了全国住院患者样本,以评估甲状腺功能减退症对植入左心室辅助装置的终末期心力衰竭患者住院结局的影响。
查询全国住院患者样本,以识别2004年至2014年期间所有接受左心室辅助装置植入的成年患者。随后将他们分为甲状腺功能减退组和非甲状腺功能减退组。主要结局是住院死亡率。其他结局包括急性肾损伤、住院时间和住院费用。建立逻辑回归模型以确定感兴趣的结局。
在该研究的2643例患者中,5.4%患有甲状腺功能减退症,94.6%没有。与非甲状腺功能减退患者相比,甲状腺功能减退患者年龄明显更大(平均年龄58.6岁对49.95岁,P值<.0001)。两组的性别构成相似。两组的住院死亡率相似。然而,甲状腺功能减退组急性肾损伤(AKI)的发生率更高(调整后的优势比[aOR]为1.83,P值<.001)。甲状腺功能减退患者的住院时间更长(调整后的平均差异[aMD]为5.19,P值.0001)。甲状腺功能减退组的住院费用也更高。
本研究发现,左心室辅助装置与甲状腺功能减退的心力衰竭患者住院时间延长有关。